Self-Amplified pH/ROS Dual-Responsive Co-Delivery Nano-System with Chemo-Photodynamic Combination Therapy in Hepatic Carcinoma Treatment
DOI: https://doi.org/10.2147/ijn.s453199
IF: 7.033
2024-04-25
International Journal of Nanomedicine
Abstract:Yu Huang, 1, &ast Shuyang Wu, 1, &ast Jingjing Li, 1, 2 Chenglin He, 1 Yanfen Cheng, 3 Nan Li, 1 Yitao Wang, 1, 4 Yihan Wu, 1 Jinming Zhang 1 1 State Key Laboratory of Southwestern Chinese Medicine Resources, School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, People's Republic of China; 2 Department of Rehabilitation Sciences, Faculty of Health and Social Sciences, Hong Kong Polytechnic University, Hong Kong, SAR, People's Republic of China; 3 Chengdu University, Chengdu, People's Republic of China; 4 Macau Center for Research and Development in Chinese Medicine, State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau, People's Republic of China &astThese authors contributed equally to this work Correspondence: Jinming Zhang; Yihan Wu, State Key Laboratory of Southwestern Chinese Medicine Resources, School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, People's Republic of China, Email ; Background: Chemo-photodynamic combination therapy has demonstrated significant potential in the treatment of cancer. Triptolide (TPL), a naturally derived anticancer agent, when combined with the photosensitizer Chlorin e6 (Ce6), has shown to provide enhanced anti-tumor benefits. However, the development of stimuli-responsive nanovehicles for the co-delivery of TPL and Ce6 could further enhance the efficacy of this combination therapy. Methods: In this study, we synthesized a pH/ROS dual-responsive mPEG- TK -PBAE copolymer, which contains a pH-sensitive PBAE moiety and a ROS-sensitive thioketal (TK) linkage. Through a self-assembly process, TPL and Ce6 were successfully co-loaded into mPEG- TK -PBAE nanoparticles, hereafter referred to as TPL/Ce6 NPs. We evaluated the pH- and ROS-sensitive drug release and particle size changes. Furthermore, we investigated both the in vitro suppression of cellular proliferation and induction of apoptosis in HepG2 cells, as well as the in vivo anti-tumor efficacy of TPL/Ce6 NPs in H22 xenograft nude mice. Results: The mPEG- TK -PBAE copolymer was synthesized through a one-pot Michael-addition reaction and successfully co-encapsulated both TPL and Ce6 by self-assembly. Upon exposure to acid pH values and high ROS levels, the payloads in TPL/Ce6 NPs were rapidly released. Notably, the abundant ROS generated by the released Ce6 under laser irradiation further accelerated the degradation of the nanosystem, thereby amplifying the tumor microenvironment-responsive drug release and enhancing anticancer efficacy. Consequently, TPL/Ce6 NPs significantly increased PDT-induced oxidative stress and augmented TPL-induced apoptosis in HepG2 cells, leading to synergistic anticancer effects in vitro. Moreover, administering TPL/Ce6 NPs (containing 0.3 mg/kg of TPL and 4 mg/kg of Ce6) seven times, accompanied by 650 nm laser irradiation, efficiently inhibited tumor growth in H22 tumor-bearing mice, while exhibiting lower systemic toxicity. Conclusion: Overall, we have developed a tumor microenvironment-responsive nanosystem for the co-delivery of TPL and Ce6, demonstrating amplified synergistic effects of chemo-photodynamic therapy (chemo-PDT) for hepatocellular carcinoma (HCC) treatment. Keywords: triptolide, PDT, ROS, Ce6, pH responsive, hepatic carcinoma Hepatocellular carcinoma (HCC), the most prevalent form of primary liver cancer, ranks as the third leading cause of cancer-related deaths and poses a significant global health challenge. Despite the availability of FDA-approved anti-HCC agents such as sofitinib and anti-PD-1/PD-L1 monoclonal antibodies, as well as traditional chemotherapeutic drugs like doxorubicin, therapeutic outcomes remain unsatisfactory, particularly for patients with unresectable HCC. Recent strategies combining photodynamic therapy (PDT) with chemotherapy have shown promise in combating HCC. 1,2 Compared to single-agent therapy, this chemo-photodynamic approach has achieved improved therapeutic outcomes with fewer side effects. 3 Successful initiatives have demonstrated the synergistic anti-HCC effects of a photosensitizer with paclitaxel and anti-PD-L1 combination. 1 Furthermore, Weinire Abuduwaili et al have developed an iridium-based photosensitizer combined with sorafenib, offering synergistic benefits for HCC treatment through chemo-photodynamic therapy. 2 Yet, innovative therapies that effectively combat HCC while minimizing side effects are still needed. Triptolide (TPL), a diterpenoid extracted from the m -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology